Latest Headlines

  1. Al Farabi Medical Laboratories and Dante Genomics Announce Global Partnership For The Delivery Of Next Generation Sequencing Genomic Testing In The Kingdom Of Saudi Arabia 11/9/2022

    Al Farabi Medical Laboratories, the leading medical laboratories in the Kingdom of Saudi Arabia with more than 50 labs covering all regions of the Kingdom, and Dante Genomics, a global leader in genomics and precision medicine, are pleased to announce a commercial partnership to provide patients with a wide range of clinical genomic tests, including Whole Genome Sequencing and Whole Exome Sequencing with interpretation, as well as Non-Invasive prenatal Testing (NIPT) in Saudi Arabia.

  2. hc1 Introduces Sendout Management™ 11/9/2022

    Today hc1, the leader in clinical insights, analytics and solutions for precision health, introduced hc1 Sendout Management™, a new solution that consolidates laboratory data to provide real-time insight into reference lab performance and cost to inform operational decisions.

  3. Life Line Screening Launches At-Home Lab Tests, Private And Convenient Health Tests Delivered To Your Home 11/8/2022

    Life Line Screening, a leader in preventive health screenings, has launched a new line of products: Life Line Home Tests. At-home lab tests are convenient, private and accurate.

  4. Sentynl Therapeutics Recognizes Menkes Disease Awareness Month, Committed To The Development Of Tests For Early Diagnosis Of Patients With Menkes Disease 11/8/2022

    Sentynl Therapeutics, Inc. ("Sentynl") a US-based biopharmaceutical company focused on bringing innovative therapies to patients living with rare disease, joins the global Menkes disease community including the Menkes Foundation ("Menkes Foundation") in recognizing the month of November as Menkes Disease Awareness Month.

  5. Cepheid Receives CE Mark For Xpert® Xpress GBS 11/7/2022

    Cepheid announced today that it has received the CE mark for Xpert® Xpress GBS, a molecular diagnostic test for the qualitative intrapartum detection of Group B Streptococcus (GBS).

  6. Biden-Harris Administration Announces $1.5B From Inflation Reduction Act To Strengthen America’s National Laboratories 11/4/2022

    The Biden-Harris Administration, through the U.S. Department of Energy (DOE), today announced $1.5 billion from President Biden’s Inflation Reduction Act to build and upgrade America’s national laboratories.

  7. Nanomix Enters Into Multi-Country Distribution Agreement For The elab System With Mast Group Limited 11/4/2022

    Nanomix Corporation (OTCQB: NNMX) (“Nanomix” or the “Company”), a leader in the development of mobile, affordable, point-of-care (POC) diagnostics, today announced that it has entered into a multi-region distribution agreement with Mast Group Limited (“Mast”), an independent world class manufacturer and supplier of diagnostic products for clinical, industrial and veterinary testing.

  8. Massachusetts’s General Hospital Study Demonstrates Prevencio’s AI-Driven HART CVE Blood Test Highly Accurate For Predicting Major Cardiac Events In Patients With Chronic Kidney Disease 11/3/2022

    Prevencio, Inc. today announces the presentation of patient data demonstrating its Artificial Intelligence (AI)-driven HART CVE blood test is highly accurate in determining whether a person with chronic kidney disease (CKD) will have a heart attack or major adverse cardiac event within the next two years.

  9. Hologic’s 3Dimensions System For 3D Mammography Receives EUREF Type Test Certification 11/3/2022

    Hologic, Inc., a global leader in women’s health, announced today that its 3Dimensions mammography system was awarded EUREF Type Test certification by the European Reference Organisation for Quality Assured Breast Screening and Diagnostic Services (www.EUREF.org).

  10. Exscientia Expands Biologics Design Capability With Automated Laboratory 11/3/2022

    Exscientia plc today announced the expansion of its platform to include the design of biologics, such as human antibodies.